These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24743259)

  • 1. Identification of a novel function of CX-4945 as a splicing regulator.
    Kim H; Choi K; Kang H; Lee SY; Chi SW; Lee MS; Song J; Im D; Choi Y; Cho S
    PLoS One; 2014; 9(4):e94978. PubMed ID: 24743259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
    Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
    Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F; Huang X; Wu M; Gou S; Hu W
    Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
    Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
    J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
    Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
    Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 5-(3-Chlorophenylamino)benzo[
    Wang Y; Lv Z; Chen F; Wang X; Gou S
    J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casein kinase 2 inhibitor CX-4945 elicits an anti-Warburg effects through the downregulation of TAp73 and inhibits gastric tumorigenesis.
    Tang S; Yuan Y; Liu Z; He Y; Pan D
    Biochem Biophys Res Commun; 2020 Oct; 530(4):686-691. PubMed ID: 32771361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
    Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
    BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines.
    Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC
    Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK2 inhibitor CX-4945 blocks TGF-β1-induced epithelial-to-mesenchymal transition in A549 human lung adenocarcinoma cells.
    Kim J; Hwan Kim S
    PLoS One; 2013; 8(9):e74342. PubMed ID: 24023938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
    Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
    J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
    So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
    PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.
    Zanin S; Borgo C; Girardi C; O'Brien SE; Miyata Y; Pinna LA; Donella-Deana A; Ruzzene M
    PLoS One; 2012; 7(11):e49193. PubMed ID: 23145120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
    Tang J; Xie Y; Huang J; Zhang L; Jiang W; Li Z; Bian J
    Bioorg Med Chem; 2022 Sep; 70():116921. PubMed ID: 35863237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
    Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
    Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
    Vahter J; Viht K; Uri A; Enkvist E
    Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
    Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
    J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.